Quantcast

Latest Sunitinib Stories

2008-08-11 09:01:39

By David Roberts A SURVEY has revealed more than 1,300 cancer patients nationwide are being denied vital drugs because of a ?postcode lottery? over who gets access to them. The Rarer Cancers Forum has found that in some areas of the country 100 per cent of patients were granted access to the medicine, whereas in others not a single person received the treatment. The information has been obtained under the Freedom of Information Act from 62 of England?s 152 primary care trusts (PCTs)....

2008-08-11 03:00:47

COVENTRY health chiefs are supporting a draft decision to reject four new cancer drugs for patients with advanced kidney cancer. The National Institute for Health and Clinical Excellence (Nice) decided that sunitinib, bevacizumab, sorafenib and Torisel are not a cost-effective use of NHS cash. For example bevacizumab costs around pounds 23,000 per patient per year. Dr Peter Barker, public health consultant at Coventry Teaching Primary Care Trust (PCT) said: "Coventry PCT is supportive...

2008-08-09 06:00:22

By Barry Nelson A CANCER patient who has survived in the past year because of a wonder drug has condemned plans to deny it to other patients because of the cost. Stan Craddock, 63, from Darlington, said he survived the past ten months because of the drug Sutent. Last night, he said he could not believe that such a powerful cancer drug was effectively going to be banned by the NHS. This followed the draft guidance from the National Institute for Health and Clinical Excellence (Nice)...

2008-08-09 03:00:08

TWO cancer sufferers from Warwickshire have been left angered by a national medical board's decision not to fund a life-lengthening wonder drug. As featured in the Telegraph, Ade Cure, from Wellesbourne, and Colin Howe, from Rugby, are both dying of kidney cancer. But PCTs in Warwickshire and Coventry won't routinely prescribe the life-prolonging drug Sutent to sufferers of kidney and gastrointestinal cancer. Their decision was backed on Thursday by the National Institute for Health and...

2008-08-08 09:00:28

By Barry Nelson NORTH-EAST health bosses say newly referred kidney cancer patients will continue to receive an expensive drug for the time being. The reassurance from the North of England Cancer Network came after Wednesday?s announcement of draft guidance rejecting four new cancer drugs. The drugs watchdog the National Institute for Health and Clinical Excellence (Nice) has turned down Sutent, Avastin, Nexavar and Torisel as being too expensive for the NHS. The watchdog?s final...

2008-08-08 09:00:28

The UK's cost-effectiveness watchdog NICE has delivered another blow to the developers of targeted cancer therapies by recommending against the use of four new kidney cancer drugs in the UK. This recommendation suggests that NICE is likely to look unfavorably on a number of other targeted therapies in development, severely limiting future growth of the targeted cancer therapies market in the UK. In its preliminary guidance report on a number of new targeted cancer therapies, the UK's...

2008-08-08 00:00:39

Britain's National Health Service said it rejected four new drugs designed to treat advanced kidney cancer because the cost is too high. The National Institute for Health and Clinical Excellence said the drugs -- Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus) -- are too expensive and the money can be better put to other use, the Times of London said Thursday. The newspaper said cancer organizations are outraged by the decision. Advocates for the...

2008-08-08 00:00:11

By Ian Johnston CAMPAIGNERS EXPRESSED outrage yesterday at a decision to deny four drug treatments to NHS patients with advanced kidney cancer. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus). This leaves patients with only one treatment option - interferon. Professor John Wagstaff, from the South Wales Cancer Institute, said there was "no...

2008-08-08 00:00:11

By JEREMY LAURANCE The big question Why are we asking this now? CANCER CHARITIES, kidney specialists and campaigners were outraged yesterday when the National Institute for Clinical Excellence (Nice), announced that it had rejected four new drugs for advanced kidney cancer as too expensive for the NHS. In draft guidance, the medicines watchdog said that the drugs can extend life by five to six months on average but they cost too much. The money would do more good if it were spent...

2008-08-07 18:00:00

By JANE KIRBY PATIENTS with advanced kidney cancer will be denied four treatments on the NHS under new guidelines published yesterday. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus). Primary care trusts in Merseyside and Cheshire had already agreed to start offering Sutent on the NHS, as reported by the Daily Post in December last year....


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related